2026 Safety and Availability Communications
This webpage was developed to provide the public with important information about the safety and availability of biological products.
September 2026
- FDA Takes Action on New Boxed Warning for Adzynma Enzyme Replacement Therapy for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
September 23, 2026 - Important Change in BabyBIG® Lot 7 Dosage Information
September 9, 2026
July 2026
- Important Information for Human Cell, Tissue, and Cellular and Tissue-based Product (HCT/P) Establishments Regarding Ebola Disease and HCT/P Donation
July 10, 2026 - Expiration Date Extension for North American Coral Snake Antivenin (Micrurus fulvius) (Equine Origin) Lot CL6814 through December 31, 2026
July 1, 2026
June 2026
- Important Information for Blood Establishments Regarding Ebola Disease and Blood Donation
June 29, 2026
May 2026
March 2026
- Expiration Date Extension for North American Coral Snake Antivenin (Micrurus fulvius) (Equine Origin) Lot CL6814 through June 30, 2026
- Patient and Consumer Warning about Potential Serious Risks of Harm following Use of Unapproved Products from Human Cells or Tissues
January 2026
- January 9, 2026 Safety Labeling Notification Letter - Fluzone
- January 9, 2026 Safety Labeling Notification Letter - Flumist
- January 9, 2026 Safety Labeling Notification Letter - Fluarix
- January 9, 2026 Safety Labeling Notification Letter - Flulaval
- January 9, 2026 Safety Labeling Notification Letter - Afluria
- January 9, 2026 Safety Labeling Notification Letter - Flucelvax